Business Wire

Sevan Names New Chief Financial Officer

28.4.2020 16:00:00 EEST | Business Wire | Press release

Share

Sevan Multi-Site Solutions, Inc. (Sevan), a global leader in innovative design, program management, construction services and data analytics, today announced Paul Evans has been named the company’s Chief Financial Officer (CFO). Evans will oversee Sevan’s global finance functions including accounting, financial planning and analysis, risk management and mergers & acquisitions. He will also play an integral role in shaping the strategic direction of the company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200428005335/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Paul Evans (Photo: Business Wire)

Evans brings more than 20 years of leadership experience to the role. Before joining Sevan, he served as Interim Chief Executive Officer and Board Member at Hill International, Chief Financial Officer at MYR Group, Chief Executive Officer at Conex Energy Corporation and Treasurer at NorthWestern Energy. His background and financial expertise include significant experience with operational management and accounting, debt and equity financing, investor relations, tax, budgeting, forecasting, audits, capital allocation, network optimization, contingency planning and information technology.

“Paul brings extraordinary experience in corporate and operational finance across a variety of industries and has been responsible for leading global teams supporting large-scale engineering and construction operations,” said Jim Evans, President and CEO of Sevan. “I am excited to have Paul join our executive office and team at such an important time for our business. I am confident Sevan will benefit from his experiences and perspective as we accelerate our path to grow.”

In December 2019, ABS Capital Partners invested $17.5 million in Sevan to support continued growth and scalability. ABS Capital Partners is a leading late-stage growth company investor.

“Sevan has grown organically for the past nine years since the company’s inception, and ABS Capital is Sevan’s first outside investor,” said Paul Evans. “I look forward to helping Sevan continue to grow in a sustainable way while providing strategic expertise through all financial operations, acquisitions, integration and beyond.”

Paul Evans earned a Master of International Management from Thunderbird School of Global Management in Phoenix, Arizona and a Bachelor of Business Administration – Accounting from Stephen F. Austin State University in Nacogdoches, Texas. He is also a Certified Public Accountant. Evans is a U.S. Army veteran, and a dual citizen of the United States and United Kingdom.

Sevan is a 450-person project management firm headquartered in Downers Grove, Illinois with an international office in London. Paul will be based out of Sevan’s headquarters.

Sevan has been recognized as an Employee-Rated Great Place to Work for six consecutive years. In 2018 Great Place to Work® and FORTUNE ranked Sevan #29 on the list of the 100 Best Medium Workplaces. A full list of awards and rankings Sevan earned to date is available on Sevan’s Website.

About Sevan

The vision of Sevan Multi-Site Solutions (Sevan) is to be the best in the world at delivering innovative design, program management, construction services and data analytics to organizations with multiple sites. Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan helps iconic global brands—including 7-Eleven, AAFES, Albertsons, BP, Bento Box, Carrols Corporation, Chipotle, DaVita, HCA Healthcare, Hallmark, Kroger, McDonald’s, Marathon, Office Depot, Starbucks, Sunoco, Walgreens Boots Alliance and Walmart. Sevan rolls out Multi-Site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes new builds, rebuilds, remodels and renovations. The company’s expertise spans numerous market sectors including banking, fuel and convenience store, government, restaurant, grocery, retail, healthcare, housing and hospitality industries. For more information, visit www.sevansolutions.com.

For more information please contact Hafsa Mahmood by calling 312.285.0590 or via e-mail at hafsa.mahmood@sevansolutions.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hafsa Mahmood
Manager, Marketing & Communications April 28, 2020
Phone: 312.285.0590
Email: hafsa.mahmood@sevansolutions.com
Website: www.sevansolutions.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye